-
SANOFI-AVENTIS U.S. LLC et al v. ACTAVIS LLC et al DC CAFC
- 3:15-cv-00776
- D.N.J.
- Judge: Michael A. Shipp +1
- Filed: 02/02/2015
- Closed: 09/26/2017
- Latest Docket Entry: 10/05/2019
- PACER
- Docket updated daily
3
Plaintiffs
2
Defendants
1
Accused
Product
2
Patents-in-Suit
968
Days in
Litigation
-
SANOFI-AVENTIS U.S. LLC et al v. ACTAVIS LLC et al DC CAFC
- 3:15-cv-00776
- D.N.J.
- Judge: Michael A. Shipp +1
- Filed: 02/02/2015
- Closed: 09/26/2017
- Latest Docket Entry: 10/05/2019
- PACER
- Docket updated daily
Cause of Action
Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Validity & Enforceability
Claim # | Claim Text | Outcome |
---|---|---|
1 |
4.alph a.-Acetoxy-2.alpha.-benzoyloxy-5.beta.,20-epoxy-1.beta.-hydroxy-7.beta.,10.beta.-dimethoxy-9-oxo-11-taxen-13.alpha.-yl(2R,3S)-3-tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate.
|
Valid (101 and 103)
Entry 27 |
2 |
A pharmaceutical composition comprising at least the product according to claim 1 in combination with one or more pharmaceutically acceptable diluents or adjuvants and optionally one or more compatible and pharmacologically active compounds.
|
Valid (101 and 103)
Entry 27 |
-
Infringement
Actavis Elizabeth LLC
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
10 mg/ml cabazitaxel injection | US 5,847,170 A |
1, 2
|
Infringement
Entry 27
|
Actavis LLC
- 1 Detail
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
10 mg/ml cabazitaxel injection | US 5,847,170 A |
1, 2
|
Infringement
Entry 27
|